Nek­tar di­vests man­u­fac­tur­ing site and reagent arm for $90M 

Nek­tar Ther­a­peu­tics is sell­ing off its on­ly man­u­fac­tur­ing fa­cil­i­ty as well as its reagent busi­ness to pri­vate eq­ui­ty firm Am­per­sand Cap­i­tal Part­ners for $90 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER